Amundi Asset Management US’s Aimmune Therapeutics AIMT Stock Holding History

Amundi Asset Management US’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,300	Closed	-$217K	–	1648
2020 Q3	$217K	Buy	+6,300	New	+$134K	﹤0.01%	1381
2020 Q2	–	Sell	-6,400	Closed	-$92K	–	1711
2020 Q1	$92K	Buy	+6,400	New	+$164K	﹤0.01%	1442
2019 Q3	–	Sell	-5,800	Closed	-$121K	–	1746
2019 Q2	$121K	Hold	5,800	–	–	﹤0.01%	1557
2019 Q1	$130K	Hold	5,800	–	–	﹤0.01%	1516
2018 Q4	$139	Buy	+5,800	New	+$150K	﹤0.01%	1454

Amundi Asset Management US's AIMT Position: Q4 2020 in Review

Amundi Asset Management US sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 6,300 shares — an estimated $217K sold.

Amundi Asset Management US first reported a position in AIMT in Q4 2018 and held it in 5 quarters. The position peaked at $217K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Amundi Asset Management US reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Amundi Asset Management US sold 6,300 Aimmune Therapeutics shares in Q4 2020, an estimated $217K.
Amundi Asset Management US first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 5 quarters.
Amundi Asset Management US's Aimmune Therapeutics position peaked at $217K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Amundi Asset Management US's 13F filing for Q4 2020, filed 16 Feb 2021.